INDIANAPOLIS / Jun 26, 2024 / Business Wire / Elevance Health (NYSE: ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:
The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. You may also access the webcast here. A webcast replay will be available following the call.
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 115 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Last Trade: | US$424.53 |
Daily Change: | -10.51 -2.42 |
Daily Volume: | 3,525,012 |
Market Cap: | US$98.460B |
January 23, 2025 October 17, 2024 July 17, 2024 April 18, 2024 April 15, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load